Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study by Camille Windsor, Adrien Joseph, Stephanie Pons, Djamel Mokart, Frederic Pène, Achille Kouatchet, Alexandre Demoule, Fabrice Bruneel, Martine Nyunga, Edith Borcoman, Matthieu Legrand, Michael Darmon, Lara Zafrani, Elie Azoulay, Virginie Lemiale

Get full text

Insulin-Sensitizing Properties of Decoctions from Leaves, Stems, and Roots of <i>Cucumis prophetarum</i> L. by Zewdie Mekonnen, Giuseppe Petito, Getasew Shitaye, Gianluca D’Abrosca, Belete Adefris Legesse, Sisay Addisu, Maurizio Ragni, Antonia Lanni, Roberto Fattorusso, Carla Isernia, Lara Comune, Simona Piccolella, Severina Pacifico, Rosalba Senese, Gaetano Malgieri, Solomon Tebeje Gizaw

Get full text

Safety and tolerability of the M2 muscarinic acetylcholine receptor modulator BAY 2413555 in heart failure with reduced ejection fraction in the REMOTE-HF study by Marat Fudim, Muhammad Shahzeb Khan, Dominik Linz, JoAnn Lindenfeld, Calum MacRae, Nina Kimmeskamp-Kirschbaum, Michaela Meyer, Thomas Mondritzki, Hanna Tinel, Wilfried Dinh, Robert J. Mentz

Get full text

Integrating pharmacogenomics and cheminformatics with diverse disease phenotypes for cell type-guided drug discovery by Arda Halu, Sarvesh Chelvanambi, Julius L. Decano, Joan T. Matamalas, Mary Whelan, Takaharu Asano, Namitra Kalicharran, Sasha A. Singh, Joseph Loscalzo, Masanori Aikawa

“…Conclusions Our network-based analytical framework integrating pharmacogenomics and cheminformatics (available at https://github.com/r-duh/Pathopticon ) provides a feasible blueprint for a cell type-specific drug discovery and repositioning platform with broad implications for the efficiency and success of drug development.…”
Get full text

Redefining NSP12 activity in SARS-CoV-2 and its regulation by NSP8 and NSP7 by Deepa Singh, Tushar Kushwaha, Rajkumar Kulandaisamy, Vikas Kumar, Kamal Baswal, Saras H. Tiwari, Arkadyuti Ghorai, Manoj Kumar, Saroj Kumar, Soumya De, Aparoy Polamarasetty, Deepak Sehgal, Madhumohan R. Katika, Suresh Gadde, Marceline Côté, Sarala R. Kayampeta, Mohan Babu Appaiahgari, Krishna K. Inampudi

“…These findings have implications for novel drug development, and compounds inhibiting NSP7 or NSP8 interactions with NSP12 can be lethal to coronavirus replication.…”
Get full text

Serine/threonine protein kinase mediates rifampicin resistance in Brucella melitensis through interacting with ribosomal protein RpsD and affecting antioxidant capacity by Yaqin Yuan, Wenqing Ning, Junjie Chen, Jiquan Li, Tianqi Xue, Cuihong An, Lingling Mao, Guangzhi Zhang, Shizhong Zhou, Jiabo Ding, Xiaowen Yang, Jianqiang Ye

“…., and the identified STPK or its pathway can serve as a potential target for new drug development against rifampicin-resistant Brucella spp.IMPORTANCENew rifampicin resistance gene in Brucella melitensis is identified via bioinformatics predictions and a whole-genome transposon mutant library, new mechanisms of rifampicin resistance in B. melitensis, and new function of serine/threonine protein kinase gene and its interaction proteins.…”
Get full text

Natural Product Identification and Molecular Docking Studies of Leishmania Major Pteridine Reductase Inhibitors by Moses N. Arthur, George Hanson, Emmanuel Broni, Patrick O. Sakyi, Henrietta Mensah-Brown, Whelton A. Miller, Samuel K. Kwofie

“…Protein–ligand interactions and molecular dynamics (MD) simulation revealed favorable hydrophobic and hydrogen bonding with critical residues, such as Lys198, Arg17, Ser111, Tyr194, Asp181, and Gly225. Crucial to the drug development, the compounds were physiochemically and pharmacologically profiled, narrowing the selection to eight compounds, excluding those with potential toxicities. …”
Get full text

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy by Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang

“…Background The current therapeutic antibodies and chimeric antigen receptor (CAR) T cells are capable of recognizing surface antigens, but not of intracellular proteins, thus limiting the target coverage for drug development. To mimic the feature of T-cell receptor (TCR) that recognizes the complex of major histocompatibility class I and peptide on the cell surface derived from the processed intracellular antigen, we used NY-ESO-1, a cancer-testis antigen, to develop a TCR-like fully human IgG1 antibody and its derivative, CAR-T cells, for cancer immunotherapy.Methods Human single-chain variable antibody fragment (scFv) phage library (~10∧11) was screened against HLA-A2/NY-ESO-1 (peptide 157–165) complex to obtain target-specific antibodies. …”
Get full text

Advancing precision therapy for colorectal cancer: Developing clinical indications for multi-target kinase inhibitor BPR1J481 using patient-derived xenograft models by Ya-Chu Tang, Jing-Jim Ou, Shu-Ching Hsu, Chih-Hsiang Huang, Li-Mei Lin, Hsin-Huei Chang, Yi-Hsin Wang, Zih-Ting Huang, Manwu Sun, Ko-Jiunn Liu, Yi-Mei Hung, Chi-Yun Lai, Chuan Shih, Chiung-Tong Chen, Jang-Yang Chang, Hsing-Pang Hsieh, Weir-Torn Jiaang, Ching-Chuan Kuo

“…However, the lack of applicable and reliable preclinical models significantly hinders the progress of drug development. Patient-derived xenograft (PDX) models are currently considered reliable in vivo preclinical models for predicting drug efficacy in cancer patients. …”
Get full text

Targeted Next-Generation Sequencing in Pneumonia: Applications in the Detection of Responsible Pathogens, Antimicrobial Resistance, and Virulence by Liu B, Bao Z, Chen W, Xi X, Ge X, Zhou J, Zheng X, Zhang P, Deng W, Ding R, Zhou M, Fang J

“…Bing Liu,1– 3,&ast; Zhiyao Bao,1– 3,&ast; Wei Chen,1– 3,&ast; Xiaotong Xi,4,5,&ast; Xiao Ge,1– 3 Jun Zhou,1– 3 Xiaoyan Zheng,6 Peipei Zhang,4,5 Wanglong Deng,4,5 Ran Ding,4,5 Min Zhou,1– 3 Jie Fang7 1Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People’s Republic of China; 2Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People’s Republic of China; 3Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, 200025, People’s Republic of China; 4State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, 210018, People’s Republic of China; 5Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, 210018, People’s Republic of China; 6Department of Pulmonary and Critical Care Medicine, Zhoushan Branch of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Zhoushan, 316000, People’s Republic of China; 7Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jie Fang, Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Rui Jin 2nd Road, Shanghai, 200025, People’s Republic of China, Email fj40517@rjh.com.cn Min Zhou, Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Rui Jin 2nd Road, Shanghai, 200025, People’s Republic of China, Email doctor_zhou_99@163.comBackground: Targeted next-generation sequencing (tNGS) is a high-throughput and cost-effective diagnostic alternative for pneumonia, with the ability to simultaneously detect pathogens, antimicrobial resistance genes, and virulence genes. …”
Get full text

Development and characterization of orthotopic patient-derived xenograft models of peritoneal metastatic mucinous appendiceal adenocarcinoma by I. Ito, V.K. Pattalachinti, A.M.G. Yousef, S. Chowdhury, M.M. Fanaeian, E. Haque, B.B. Gunes, M. Yousef, E.R. Salle, M.A. Zeineddine, S. Ji, R. Li, W. Wang, B.A. Helmink, M.W. Taggart, M.G. White, K.F. Fournier, N.W. Fowlkes, J.P. Shen

“…The lack of preclinical models of AA has hindered drug development and is a major factor in why AA remains without a single Food and Drug Administration-approved systemic treatment. …”
Get full text

5-deoxy-rutaecarpine protects against LPS-induced acute lung injury via inhibiting NLRP3 inflammasome-related inflammation by Jinque Luo, Jinque Luo, Xin Li, Xin Li, Li Zhang, Li Zhang, Meijing Deng, Jieyang Zhao, Jinghuan Zhang, Wenyu Tang, Qinghua Guo, Ling Wang

Get full text

Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis [version 2; peer review: 1 approve... by Spyridon Siafis, Johannes Schneider-Thoma, Alexandra Bannach-Brown, Oliver D. Howes, Virginia Chiocchia, Ulf Tölch, Natascha I. Drude, Sabine M. Hölter, Andrea de Bartolomeis, Anthony C. Vernon, Georgia Salanti, Sridhar Natesan, Stefan Leucht, Irene Bighelli, Sameer Jauhar, Ioannis Mantas, Josef Priller, Francesca Tinsdeall, Wulf-Peter Hansen, Fiona J. Ramage, Nobuyuki Nomura, Malcolm R. Macleod

“…Therefore, we aim to synthesize evidence on the preclinical efficacy of muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis to provide unique insights and evidence-based information to guide drug development. Methods We plan a systematic review and meta-analysis of in vivo animal studies comparing muscarinic receptor agonists or positive allosteric modulators with control conditions and existing D2R-blocking antipsychotics in animals subjected to any method that induces behavioural changes of relevance for psychosis. …”
Get full text

Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice by Aurélien Marabelle, Louis Meyblum, Lambros Tselikas, Thierry de Baere, Sandrine Susini, Fréderic Deschamps, Baptiste Bonnet, Céline Chevaleyre, Benoit Jego, Dimitri Kereselidze, Vincent Lebon, Charles Truillet

“…This immunoPET approach is applicable for clinical practice to support evidence-based drug development.…”
Get full text

Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in context by Wenqian Liu, Mo Yang, Nanxing Wang, Xiangrong Liu, Chaoyu Wang, Kaibin Shi, Fu-Dong Shi, Yuesong Pan, Mingjun Zhang, Zhiwei Sun, Yongjun Wang, Yilong Wang

“…Summary: Background: Central nervous system (CNS) accessibility constitutes a major hurdle for drug development to treat neurological diseases. Existing drug delivery methods rely on breaking the blood-brain barrier (BBB) for drugs to penetrate the CNS. …”
Get full text

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budi... by Toshio Shimizu, Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Talia Golan, Anthony Tolcher

Get full text

Biofabrication of brain-like living tissue: structure to intelligence by Ling Wang, Sen Wang, Yingjie Liu, Bowen Zhang, Zhaoyu Pan, Luge Bai, Siqi Yao, Chenrui Zhang, Huangfan Xie, Jiankang He, Dichen Li

“…Brain diseases are among the leading threats to human life, yet our understanding of their pathogenic mechanisms and drug development remains limited, largely due to the lack of accurate brain-like tissue models that replicate its complex structure and functions. …”
Get full text

Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases by Ana I. Rojo, Brigitta Buttari, Susana Cadenas, Ana Rita Carlos, Antonio Cuadrado, Ana Sofia Falcão, Manuela G. López, Milen I. Georgiev, Anna Grochot-Przeczek, Sentiljana Gumeni, José Jimenez-Villegas, Jarosław Olav Horbanczuk, Ozlen Konu, Isabel Lastres-Becker, Anna-Liisa Levonen, Viktorija Maksimova, Charalambos Michaeloudes, Liliya V. Mihaylova, Michel Edwar Mickael, Irina Milisav, Biljana Miova, Patricia Rada, Marlene Santos, Miguel C. Seabra, Dubravka Svob Strac, Sandra Tenreiro, Ioannis P. Trougakos, Albena T. Dinkova-Kostova

“…This review is a comprehensive summary of the most commonly used model organisms of NCDs in which NRF2 has been genetically or pharmacologically modulated, paving the way for drug development to combat NCDs. We discuss the validity and use of these models and identify future challenges.…”
Get full text

The TB27 Transcriptomic Model for Predicting Mycobacterium tuberculosis Culture Conversion by Maja Reimann, Korkut Avsar, Andrew DiNardo, Torsten Goldmann, Gunar Günther, Michael Hoelscher, Elmira Ibraim, Barbara Kalsdorf, Stefan Kaufmann, Niklas Köhler, Anna Mandalakas, Florian Maurer, Marius Müller, Dörte Nitschkowski, Ioana Olaru, Cristina Popa, Andrea Rachow, Thierry Rolling, Helmut Salzer, Patricia Sanchez-Carballo, Maren Schuhmann, Dagmar Schaub, Victor Spinu, Elena Terhalle, Markus Unnewehr, Nika Zielinski, Jan Heyckendorf, Christoph Lange

“…TB27 is a potential useful biomarker for anti-tuberculosis drug development and for prediction of treatment responses in clinical practice.  …”
Get full text

Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease by Daniel C Sadowski, Charles N Bernstein, Alain Bitton, Ken Croitoru, Richard N Fedorak, Anne Griffiths, the CAG Crohn’s Consensus Group

“…However, recent clinical findings and drug developments warrant a review and update of these guidelines.…”
Get full text